Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma
- PMID: 31472914
- DOI: 10.1016/j.soc.2019.06.015
Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma
Abstract
In the past decade, there has been significant progress in the treatment of primary liver cancer. There has been increasing knowledge of the molecular alterations occurring in these tumors, which is now being translated into patient care. Ongoing clinical trials will further advance the therapeutic options available to patients, including the introduction of molecular targeted therapeutics and immunotherapy approaches. Critical to the success of these new drugs, is the appropriate use of them in the clinic to maximize efficacy and limit toxicity.
Keywords: Cholangiocarcinoma; HCC; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Systemic treatment; Targeted therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.Surg Oncol Clin N Am. 2015 Jan;24(1):187-98. doi: 10.1016/j.soc.2014.09.009. Epub 2014 Oct 12. Surg Oncol Clin N Am. 2015. PMID: 25444475 Review.
-
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.Clin Colorectal Cancer. 2019 Jun;18(2):81-90. doi: 10.1016/j.clcc.2019.02.005. Epub 2019 Feb 27. Clin Colorectal Cancer. 2019. PMID: 30905548 Review.
-
Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?J Gastrointest Cancer. 2015 Jun;46(2):161-5. doi: 10.1007/s12029-015-9690-7. J Gastrointest Cancer. 2015. PMID: 25662892 Free PMC article. No abstract available.
-
Novel targeted treatment options for advanced cholangiocarcinoma.Expert Opin Investig Drugs. 2018 Sep;27(9):709-720. doi: 10.1080/13543784.2018.1512581. Epub 2018 Aug 30. Expert Opin Investig Drugs. 2018. PMID: 30124336 Review.
-
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.Br J Cancer. 2022 Jan;126(1):10-23. doi: 10.1038/s41416-021-01453-3. Epub 2021 Aug 16. Br J Cancer. 2022. PMID: 34400801 Free PMC article. Review.
Cited by
-
DEPDC1B promotes development of cholangiocarcinoma through enhancing the stability of CDK1 and regulating malignant phenotypes.Front Oncol. 2022 Dec 6;12:842205. doi: 10.3389/fonc.2022.842205. eCollection 2022. Front Oncol. 2022. PMID: 36568241 Free PMC article.
-
Cholangiocarcinoma.Cancer Treat Res. 2024;192:165-184. doi: 10.1007/978-3-031-61238-1_9. Cancer Treat Res. 2024. PMID: 39212921 Review.
-
The Effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery.Am J Transl Res. 2021 Jun 15;13(6):6638-6645. eCollection 2021. Am J Transl Res. 2021. PMID: 34306407 Free PMC article.
-
Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.BMC Cancer. 2023 Oct 19;23(1):1007. doi: 10.1186/s12885-023-11463-4. BMC Cancer. 2023. PMID: 37858061 Free PMC article.
-
Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma.Pak J Med Sci. 2024 Sep;40(8):1663-1668. doi: 10.12669/pjms.40.8.8982. Pak J Med Sci. 2024. PMID: 39281258 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous